16 December 2016
Medicines Australia has appointed Dr Anna Lavelle as an independent Board member following a comprehensive recruitment process.
The appointment follows her recent retirement from AusBiotech where she served for eleven years as the CEO of the industry association which represents Australia’s growing biotechnology sector.
Medicines Australia Chairman Mr Wes Cook said: “Dr Lavelle is a talented, well respected person within the innovative pharmaceutical and biotechnology sector who will now bring her years of experience to our Board.”
“For more than 25 years, Dr Lavelle has served on the boards of not-for-profit, government and for-profit entities.”
“Dr Lavelle is well known to all of our members and already has a reputation as an industry leader and trusted advisor.”
“She has strong governance skills and has a lengthy track record in healthcare delivery, technology development and government policy.”
“As the independent Board member, Dr Lavelle will play a critical role in Board governance but is also well qualified to provide advice to the Board and our members on relevant policy issues for our sector,” Mr Cook said.
Chief Executive Milton Catelin said, “I want to congratulate Dr Lavelle on this important appointment and I look forward to working closely with her in the months ahead.”
“I would also like to thank all of those who applied for the Independent Director role. There were many talented, experienced applicants which is a wonderful sign of the high regard there is for this important industry,” said Mr Catelin.
Dr Lavelle will also Chair the soon to be created Medicines Australia Advisory Council which will be made up of senior leaders from the membership as well as leaders from the broader health science sector.
An announcement of the Advisory Council appointees will be made early in the New Year.